Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma

Background. Renal cell carcinoma accounts for about 2-3% of all malignant tumors. The prevalence of brain metastases from RCC is less than 20% of cases. Traditionally, whole brain radiotherapy as well as the latest stereotactic radiosurgery improves both survival and local tumor control. These treat...

Full description

Saved in:
Bibliographic Details
Main Authors: Michela Roberto, Maria Bassanelli, Elsa Iannicelli, Silvana Giacinti, Chiara D’Antonio, Anna Maria Aschelter, Paolo Marchetti
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:Case Reports in Oncological Medicine
Online Access:http://dx.doi.org/10.1155/2015/629046
Tags: Add Tag
No Tags, Be the first to tag this record!